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ABSTRACT OF THESIS 
 
INTERACTION OF ISOFLAVONES AND ENDOPHYTE-INFECTED TALL FESCUE SEED EXTRACT 
ON VASOACTIVITY OF BOVINE MESENTERIC VASCULATURE 
 
Endophyte-infected tall fescue produces many ergot alkaloids, which have been shown 
to be vasoconstrictive in various vessel types of bovine. On the other hand, substantial 
evidence has been reported on the vasodilative effects of formononetin and biochanin A 
in different vessel types in humans and rats. So, a study was conducted using mesenteric 
vasculature collected from heifers shortly after slaughter. After 2-h incubation with 
formononetin (F), biochanin A (B), or an ergovaline-containing tall fescue seed extract 
(EXT) and their combinations, vessels were mounted in a multi-myograph to determine 
their ergotamine-induced contractility. Results indicated that F and B at 1 × 10-6 M and 
their combination did not impact the contractile response to ergotamine in mesenteric 
vasculature. The pre-myograph incubation of mesenteric vasculature with EXT altered the 
contractile response manner to ergotamine. However, at higher concentration, F and B 
may alleviate the reduction of vasoconstriction caused by prior exposure to EXT. To our 
knowledge, this study was the first to investigate the interaction of ergot alkaloids and 
isoflavones on in vitro bovine mesenteric vasculature. However, further investigations are 
necessary to understand the mechanism behind the interaction of ergot alkaloids and 
isoflavones on vasoactivity. 
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Chapter 1. Literature Review 
Ergot Alkaloids 
History 
Ergot alkaloids have been playing important roles, as toxins and natural 
pharmaceuticals, throughout human history. It has been speculated that ergot alkaloids 
which induced hallucinations were the culprit four thousand years ago in the Eleusinian 
Mysteries of ancient Greece (Wasson et al., 1978). Although used in obstetrics as early as 
1100 B.C. for their medicinal effects (Schiff, 2006), poor understandings of their 
physiological effects and toxicodynamics limited the beneficial uses of ergot alkaloids in 
these early times.  
During the Middle Ages, several bizarre epidemics outbroke in various medieval 
European countries and killed thousands of people (Wasson et al., 1978; Schiff, 2006). 
Those outbreaks are now understood and have been attributed to long-term ergot 
poisoning, also termed as ergotism (Caporael, 1976). The cause of ergotism is indirect 
ingestion of ergot alkaloids from ergot-contaminated grains (Strickland et al., 2011). Two 
different forms of toxic symptoms were characterized from these ergotism outbreaks. 
The first form was described as gangrenous form (Ergotismus gangraenosus) (Schiff, 
2006), also referred to as “Holy fire”, or “St. Anthony’s fire”, which vividly portrays the 
severe burning pain (“fire”) in the extremities (Wasson et al., 1978; Flieger et al., 1997; 
Schiff, 2006). It is now obvious that prominent peripheral vasoconstriction initiated the
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swelling and extreme burning pain of limbs, and eventually caused gangrene (Flieger et 
al., 1997).   
The second type of symptoms was called the convulsive form (Ergotismus 
convulsivus) (Schiff, 2006).  Persons with this type developed delirium and hallucinations 
in Eleusinian Mysteries of ancient Greece as Wasson et al. (1978) speculated. However, 
recent incidence of ergotism has been very scarce and results from the achievements in 
agriculture in terms of genetics and management and on techniques of grain sanitization 
which removes most of the sclerotia (Flieger et al., 1997).  
With improved understanding of ergot alkaloids, their beneficial uses have been 
discovered. Examples of their pharmacological effects include: cerebrovascular 
insufficiency, prolactin inhibition, treatment of Parkinsonism, thrombosis, stimulation of 
cerebral and peripheral metabolism, venous insufficiency, uterine stimulation, and as a 
dopaminergic agonist (Aellig et al., 1978). 
The first ergot alkaloids (ergotoxine, which later found to be a mixture of four 
alkaloids) were isolated by G. Barger and H. Dale in 1906 (De Costa, 2002). Ergotamine, 
as the first pure alkaloid, was isolated by Arthur Stoll in 1918 (Peroutka, 1996). Isolated 
pure ergot alkaloids allowed researchers to have a closer look at their structures and 
chemistry, which is highly beneficial for understanding and further exploitation of their 
medical benefits. Nowadays, researchers are focusing on molecular, biological and 
biochemical investigations in terms of ergot alkaloid biosynthesis (Wallwey and Li, 2011).    
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Chemistry of Ergot Alkaloids 
So far, approximately 50 natural ergot alkaloids have been characterized (Flieger 
et al., 1997). The common structural feature of all ergot alkaloids is a tetracyclic ergoline 
ring system (Figure 1.1) (Garner et al., 1993; Flieger et al., 1997; Schiff, 2006; Strickland 
et al., 2011), with nitrogen methylated at the 6 position and carbon substituted variously 
at 8 position. From a biosynthetic perspective, the indole moiety is derived from 
tryptophan (Bu'Lock and Barr, 1968). Acetate is metabolized to 
dimethylallylpyrophosphate, which is found in many biological systems (Garner et al., 
1993). In many ergot alkaloids, a double bond usually exists between C-8 and C-9 or C-9 
and C-10. The position of the double bond permits compounds to have epimers, which is 
reported to not only have different sensitivities to temperature and solvents (Hafner et 
al., 2008), but also differing biological potency in animal systems (Berde and Stürmer, 
1978; Berde, 1980). Based on the different type of substitutes on C-8 of ergoline ring, 
ergot alkaloids are classified into three groups: 1) clavine alkaloids, 2) lysergic acid and its 
simple amides (derivatives), 3) ergopeptine alkaloids (Figure 1.2) (Lyons et al., 1986; 
Porter, 1995; Schardl et al., 2006; Wallwey and Li, 2011). As shown in Figure 1.2, clavine 
alkaloids generally are 6, 8-dimethylergolines with a few exceptions, such as chanoclavine, 
which has a 6, 7-Seco ring. Lysergic acid is characterized as a substituted carboxyl group 
on C-8 of ergoline ring. Amidation of the carboxyl group on C-8 derives the lysergic acid 
amide (Schiff, 2006). Due to their high pharmacological activity, lysergic acid amide, such 
as ergometrine and methylergometrine, have been used to prevent and treat postpartum 
hemorrhage (De Costa, 2002; Rajan and Wing, 2010).  
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The third group, ergopeptine alkaloids, are structurally characterized as lysergic 
acid derivatives with a tripeptide moiety attached to its carboxy group by peptide-like 
amide bonds (Figure 1.3) (Wallwey and Li, 2011). Various substitutions at R1 and R2 
accounts for the diversity of ergopeptine alkaloids (Table 1.1).  
Among ergopeptines, ergovaline and ergotamine commonly draw more attention 
of researchers. Lyons et al. (1986) reported that ergovaline was the predominant (84 to 
97%) alkaloids of all the five detected ergopeptine alkaloids from tall fescue (Lolium. 
arundinaceum) pasture. Both ergovaline and ergotamine are vasoconstrictive and 
therefore have some therapeutically significant properties, especially ergotamine and its 
derivatives which have been used as a therapy for vascular headaches, such as migraines 
(Schiff, 2006). The structural similarities of ergoline ring to the biogenic amines, dopamine, 
epinephrine, norepinephrine, serotonin, explains many of the biological effects of ergot 
alkaloids at the cellular or molecular level (Weber, 1980). The “mistaken” recognition and 
binding by biogenic amine receptors renders ergot alkaloids active in some of the 
biological agonist roles.  This is  the pharmacological rationale of ergot alkaloids as they 
are applied to treat rhage, migraine, venostasis, hyperprolactinemia and Parkinson’s 
disease (Berde, 1980).   
Natural Sources of Ergot Alkaloids 
Naturally, ergot alkaloids are produced by fungal endophytes, mainly within the 
Hypocreales and Eurotiales orders. Claviceps genus under Hypocreales order have been 
known and parasitize more than 600 plants (Strickland et al., 2011). Claviceps sclerotia 
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were also found in several important grains such as barley, wheat, rye, millet, and oats 
(Bové, 1970; Groger, 1972), which was the major culprit of the ergotism outbreaks during 
the Middle Ages in Europe.  
Since Stoll first isolated and identified ergotamine from Claviceps sclerotia (Stoll, 
1952), several other endophytic fungi genus such as Epichloë, Neotyphodium, and 
Balansia, have been proven to produce ergot alkaloids on contaminated plants (Bacon, 
1988; Flieger et al., 1997; Clay and Schardl, 2002). However, the production of ergot 
alkaloids varies depending on the interactions of different fungi and plants. For example, 
fungi Aspergillus and Penicillium possess a lower capability of producing ergot alkaloids 
than Claviceps (Reshetilova and Kozlovskii, 1990; Flieger et al., 1997).  
On the other hand, ergot alkaloids are distributed differently within the plant. For 
instance, ergot alkaloid concentrations in tall fescue from high to low is generally seed, 
crown, stems, leaves, and roots (Rottinghaus et al., 1991; Azevedo and Welty, 1995). 
What’s more, environmental factors (growth temperature, humidity, soil fertility) also 
play big roles in impacting the growth of certain fungi and further regulating the 
production of ergot alkaloids. The symbiotic interactions between plants and endophytic 
fungi benefit the host in terms of the greater resistance to insects, herbivores, pathogens, 
as well as enhanced environmental tolerance and overall competitiveness. Even though 
the endophyte infected grains are no longer an ergotism risk for humans, the ergot 
alkaloids produced by these endophytes, especially Neotyphodium coenophialum-
infected tall fescue (L. arundinaceum), hamper livestock production (Strickland et al., 
2011).  
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Fescue Toxicosis and Its Influence on Livestock 
Tall fescue [Lolium arundinaceum (Schreb.) Darbysh.] is the most widely 
distributed cool-season perennial pasture grass in the world. Although tall fescue is a 
native of Europe, it has been distributed and cultivated in North and South America, 
southern Africa, Australia, New Zealand, and eastern Asia (Hannaway et al., 2009). Tall 
fescue is the predominant temperate pasture grass grown within the transition zone of 
the eastern and central part of the United States (Strickland et al., 2009a), covering 
approximately 15 million ha (Buckner et al., 1979).  
With the wider occurrence and application of tall fescue in pastures, there were 
reports of grazing animal having health problem and poor performance (Pratt and Haynes, 
1950; Pratt and Davis, 1954). Following this, several grazing studies found gains of beef 
steers on tall fescue were significantly lower than on orchardgrass (Dactylis glomerata L.) 
(Blaser et al., 1956; Mott et al., 1971; Harris, 1972). Other than decreased bodyweight 
gains and cow conception rates (Petritz et al., 1980), three major disorders have been 
observed and characterized (Stuedemann and Hoveland, 1988).  
Fescue foot is considered the most dramatic visible symptom which was first 
reported by Cunningham (1949) in New Zealand. The incidence was usually higher in cold 
weather with the signs: stiffness and soreness of tissue (dry gangrene) appearing near the 
end of hoof or tail, lameness in hind quarters, loss of tail switch (Cunningham, 1949). 
These disorders are similar with the symptoms of gangrenous form ergotism, which is 
caused by the vasoconstrictive effect of ergot alkaloids on extremities.  
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The other two symptoms, summer slump and fat necrosis, have been intensively 
reviewed (Bush and Buckner, 1973; Strickland et al., 1993; Strickland et al., 2009a; Waller, 
2009) and are characterized by reduced bodyweight gain, rough hair coat, elevated body 
temperature and respiration rate, reduced milk production, lesser tolerance of heat. In 
general, these three typical symptoms belong to a more comprehensive toxicity 
syndrome, termed as tall fescue toxicosis (also known as fescue toxicosis) (Strickland et 
al., 2009a).  
The first conclusive evidence was unclear until Bacon et al. (1977) and coworkers 
first reported that the presence of an endophytic fungi, Epichloë typhina, in tall fescue 
which associated with fescue toxicosis. Later, this endophyte was renamed as 
Acremonium coenophialum, and then Neotyphodium coenophialum (Morgan-Jones and 
Gams, 1982).  Unsurprisingly, the clavine alkaloids and lysergic acid amides (Porter et al., 
1981; Yates and Powell, 1988; Yates et al., 1989; Petroski and Powell, 1991), and 
ergopeptine alkaloids (Yates et al., 1985; Lyons et al., 1986; Yates and Powell, 1988) were 
all detected from Neotyphodium coenophialum-infected tall fescue.  
In combination with the symptom similarity of fescue toxicosis and ergotism, ergot 
alkaloids are most likely the causative agents of fescue toxicosis. As proved later by many 
researchers, ungulates’ consumption of ergot alkaloids produced by Neotyphodium 
coenophialum-infected tall fescue induces the fescue toxicosis, which is considered as the 
main grass-induced toxicosis in the United States (Cheeke, 1995). Considering tall fescue’s 
prevalence as pasture grass in the southeastern United States, it is self-evident that the 
economic loss on livestock production of fescue toxicosis is profound. In United States, 
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the annual economic losses from decreased conception rates and weaning weights of 
beef cattle grazing endophyte-infected tall fescue were conservatively estimated at $609 
million (Hoveland, 1993). When taking into account the influences on the equine and 
small ruminant industries, as well as calculations based on today’s dollars, the overall 
annual losses are estimated to exceed 1 billion dollars (Strickland et al., 2011). Admittedly, 
a comprehensive solution to fescue toxicosis has not been proposed so far, neither as a 
systematic mechanism of ergot alkaloids on different physiology systems of domestic 
animals. Nevertheless, a great deal of research has been and will be conducted to better 
understand the toxicodynamics of fescue toxicosis and to further explain the complex 
interaction among the animal, ergot alkaloids, plant, endophyte and environmental 
factors involved (Strickland et al., 2011). 
Toxicodynamics 
Grazing endophyte-infected tall fescue induces several disorders of different 
physiological systems (gastrointestinal, reproduction, cardiovascular, etc.) (Strickland et 
al., 2011) which are summarized in general as fescue toxicosis. In terms of seeking more 
comprehensive and effective solutions of fescue toxicosis, it is vital to thoroughly 
understand the physiological mechanisms behind every fescue toxicosis induced disorder. 
It has been intensively reviewed in regard to the impact of ergot alkaloids from toxic 
endophyte-infected tall fescue on the animals microbial ecology, gastrointestinal system, 
neural and neuroendocrine systems, reproductive system, immune system, 
cardiovascular system, and the possible toxicodynamics associated with them (Strickland 
et al., 2009a; Strickland et al., 2011). In this section, the major focus will be located on the 
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ergot alkaloids’ impact on cardiovascular system, especially on core or peripheral blood 
vascular function and the potential mechanism behind them.  
As mentioned previously, grazing endophyte-infected tall fescue results in major 
impacts on vascular function, which leads to the symptoms of gangrene of extremities 
and elevated body temperature. In support, research findings tend to favor ergot 
alkaloids as the primary causative agents of fescue toxicosis (Solomons et al., 1989; Oliver 
et al., 1992; Oliver et al., 1993; Strickland et al., 1996; Oliver et al., 1998; Klotz et al., 2006; 
Klotz et al., 2007), especially in consideration of their biological activities on blood vessels. 
Two primary effects of ergot alkaloids on cardiovascular systems of domestic animals 
have been summarized (Strickland et al., 2011). First, immediate reduction of heart rate 
appears at 4 hours after E+ tall fescue consumption, and gradually returns back to pre-
exposure level in about 172 hours (McLeay et al., 2002; Aiken et al., 2007; Aiken et al., 
2009). Second, vasoconstriction and possible morphological changes (such as smooth 
muscle cell hyperplasia and endothelial cell damage) of blood vessels (Rhodes et al., 1991; 
Strickland et al., 1996; Oliver and Schultze, 1997; Shappell, 2003; Aiken et al., 2007; Aiken 
et al., 2009). This section will mainly focus on the effects of ergot alkaloids on vascular 
function (i.e., vasoconstrictive effects, changes of smooth muscle cell and endothelial cell), 
and the mechanisms currently thought to be involved.  
Effects on Vascular Smooth Muscle 
Vascular smooth muscle is the middle of the three concentric layers of blood 
vessels, and is important in regulating the caliber of the blood vessels by contraction or 
 10 
 
 
relaxation (Strickland et al., 2009b). Endothelium lines the interior surface of blood 
vessels and regulates vascular homeostasis by interacting with a variety of paracrine 
factors (Vita and Keaney, 2002). Symptoms of fescue foot were first induced in calves 
given ethanolic extracts of tall fescue hay (Williams et al., 1975). They also reported that 
calves that had fescue foot had concomitant thickening of vessel walls and smaller vessel 
lumens in blood vessels of the coronary bands and tail tips. Garner and Cornell (1978)  
reported similar observations with a thickening of the smooth muscle layer of peripheral 
blood vessels after consumption of endophyte-infected tall fescue. However, it was 
unclear whether the growth of smooth muscle cells is based on a mechanism of 
hyperplasia or hypertrophy. Later, the findings of Strickland et al. (1996) appear to favor 
hyperplasia over hypertrophy as a possible mechanism. They reported that ergonovine, 
ergovaline and α-ergocryptine stimulate the growth of quiescent bovine vascular smooth 
muscle cells in vitro. However, inhibitory effects of bromocriptine (a semisynthetic 
derivative of peptide alkaloids) on growing vascular smooth muscle cell proliferation was 
observed in vitro in the rat and human (Zhang and Cincotta, 1997). Similarly, ergovaline 
inhibited the growth of growing bovine vascular smooth muscle cells (Strickland et al. 
(1996).  
Effects on Vascular Endothelium 
The endothelium is also highly suspected to be impacted by ergot alkaloids 
(Strickland et al., 2009b). There was a debate based on whether ergot alkaloids have 
direct influence on endothelial cells or not. One argument was that instead of toxic effects 
of ergot alkaloids (ergotamine), blood vasoconstriction caused endothelial damage (Lewis 
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and Gelfand, 1935). These workers found that a necrosis was induced in the fowl’s comb 
by ergotamine and further concluded that vasoconstriction alone did not necessarily 
cause gangrene until the endothelial damage appears as a consequence of prolonged 
vasoconstriction. Their point of view was supported by Thompson et al. (1950) who 
reported a migrainous case subject with non-gangrenous arteriospam with no organic 
changes in the small vessels. On the other hand, ergot alkaloids were reported to induce 
bovine dorsal pedal vein endothelial cell death in cultures (Shappell, 2003). In 
consideration of the concentration of ergot alkaloids used in this study was relatively 
higher than natural grazing scenarios and further research is needed to support Shappell’s 
argument.  
Vasoconstrictive Effects 
Regardless of the contradictory findings in vascular smooth muscle cell and 
endothelial cell, ergot alkaloids have produced vasoconstrictive effects in a variety of in 
vivo and in vitro research. Due to the intimate relationship of fescue toxicosis symptoms 
(e.g., gangrene in extremities and elevated body temperatures) and peripheral 
vasoconstriction, caudal artery (Aiken et al., 2007; Aiken et al., 2009), dorsal pedal vein 
(Solomons et al., 1989) and lateral saphenous vein (Klotz et al., 2006) have been used by 
several studies as a peripheral blood vessel model. Other models [e.g., right ruminal 
artery and vein (Klotz et al., 2011), mesenteric artery and vein (Klotz, 2014)] have also 
been developed in order to investigate the effects of ergot alkaloids on core blood vessels 
and their interaction with nutrient absorption.  
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However, there is only one published paper focusing on the effects of whole body 
vasculature by ergot alkaloids in sheep and cattle (Rhodes et al., 1991). Using radiolabeled 
microspheres, they reported that reduced (P < 0.10) blood flow occurred lower in hind 
leg skin and adrenal glands by wethers fed a high alkaloid (1.18 ppm ergovaline) diet. 
Similar blood flow reductions to the rib skin (P = 0.002), duodenum (P = 0.084), colon (P 
= 0.080) and kidney (P = 0.118) were reported in cattle fed a high endophyte (0.52 ppm 
ergovaline) diet under high ambient temperatures (32℃.) (Rhodes et al., 1991). These 
findings might explain the higher rectal temperature of animals exposed to endophyte-
infested tall fescue. The constricted blood vessel reduces its vessel caliber and therefore 
limits the blood flow to peripheral tissues, which results in inefficiency of body heat 
dissipation from core body to the surface (Strickland et al., 2009a).  
Several other in vivo studies have been conducted to investigate the 
vasoconstrictive effects of ergot alkaloids on peripheral blood vessel models. A modified 
mercury-in-rubber strain gauge and plethysmographic from human limb model (Whitney, 
1953) was used to measure the blood flow in the tail of dairy Heifers (Walls and Jacobson, 
1970). They reported that heifers treated with an alcoholic extract of fescue hay (likely 
contains ergot alkaloids) showed a decreased blood flow in the tail.  Aiken and colleagues 
conducted two experiments to investigate the hemodynamic responses of the caudal 
artery by using color Doppler ultrasonography (Aiken et al., 2007; Aiken et al., 2009). They 
found a decreased caudal artery area and blood flow after heifers exposed to endophyte 
infested tall fescue.  
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An in vivo trial was designed to evaluate the impact of ergot alkaloids on 
reticuloruminal epithelial blood flow at thermoneutral (22 ℃) and heat stress (32 ℃) 
(Foote et al., 2013). The epithelial blood flow was measured as ruminal clearance of D2O 
corrected for influx of physiological water and liquid outflow. They reported that ergot 
alkaloids from an endophyte infected tall fescue seed extract (0.015 mg ergovaline · kg 
BW-1·d-1) caused at least a 50% reduction in epithelial blood flow of steers regardless of 
temperature. In addition, a reduced VFA absorption was observed and suspected to be 
associated with the reduction in blood flow to the absorptive surface of the foregut (Foote 
et al., 2013). 
A series of bioassays have been developed to address the effects of ergot alkaloids 
on blood vascular functions in livestock. This approach allows researchers to investigate 
the effects of individual ergot alkaloid on certain target blood vessels, while in vivo trials 
are extremely difficult to create these specific combinations (Strickland et al., 2009b). 
Therefore, this methodology is not only suitable to studies looking at detailed dose 
response of certain ergot alkaloids and blood vessel combinations, but also is able to 
evaluate and compare the vasoconstrictive potency and efficacy of individual ergot 
alkaloids. What’s more, the direct dose of ergot alkaloids to target blood vessels in vitro 
will eliminate the possible interference that may be induced from the interactions of 
ergot alkaloids with other physiological systems. As mentioned in the previous section, 
the differences in ergot alkaloids on chemical structure and abundance in endophyte 
infested tall fescue has raised the question of which single ergot alkaloid contributes more 
to the vasoconstriction? In other words, the potency and efficacy have become the 
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interest of many studies, in terms of understanding the pharmacological mechanism of 
ergot alkaloid on vasculature.  
An in vitro bioassay based on bovine dorsal pedal vein was developed by Solomons 
et al. (1989) and reported that ergotamine, agroclavine and ergosine were able to elicit 
constriction of bovine dorsal pedal vein. Ergotamine induced the highest maximal 
contractile force, as well as required the lowest concentration to induce a constrictive 
response. A series of studies, using a similar bioassay, have been conducted to investigate 
the potency and efficacy of certain ergot alkaloids on bovine lateral saphenous vein 
(model of peripheral vessels) (Klotz et al., 2006; 2007; 2008, 2010; Pesqueira et al., 2014). 
Ergotamine and ergovaline produced similar contractile responses on saphenous veins in 
terms of initial contractile responses (both at 1×10-8 M) and maximum contractile tension 
(Klotz et al., 2007). However, lysergic acid was reported to induce an appreciable 
contractile response at 1×10-4 M, and where maximum contractile force was achieved 
(15.6 ± 2.3% of norepinephrine response) (Klotz et al., 2006). Based on these, it is 
reasonable to say ergotamine and ergovaline are more toxic to bovine lateral saphenous 
vein than lysergic acid, with at least 1000-fold more potency and 5-fold more efficacy 
(Strickland et al., 2011).  
Other ergot alkaloids, ergonovine, α-ergocryptine, ergocristine, and ergocornine 
induced contractile responses on the saphenous vein, and potency and efficacy were 
intermediate to ergovaline and lysergic acid (Klotz et al., 2010). The structural differences 
among ergot alkaloids were thought to impact their affinity or mode of binding to 
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serotonin receptors (Choudhary et al., 1995), which could result in different contractile 
response and potency. 
Other than peripheral vessel models (i.e., dorsal pedal vein, lateral saphenous 
vein), this bioassay have been applied on core vessels such as the right ruminal artery and 
vein (Foote et al., 2011; Klotz et al., 2011), and mesentery artery and vein (Egert et al., 
2014) to determine the effects of ergot alkaloids on vascular function and further 
interactions with gut physiology. Derived from their previous peripheral lateral 
saphenous vein model (Klotz et al., 2006), Klotz et al. (2011) developed and validated a 
vascular contractility bioassay using bovine right ruminal artery and vein, to determine 
the vasoconstrictive potentials of ergovaline, ergotamine, ergocryptine, ergocristine, 
ergonovine, ergocornine and lysergic acid (Foote et al., 2011). They reported, in both 
vessel types, lysergic acid failed to induce a contractile response, which was contradicted 
to the findings that lysergic acid is vasoconstrictive on the lateral saphenous vein (Klotz 
et al., 2006; Klotz et al., 2008). However, the appreciable contractile response was not 
observed until lysergic acid at 10-4 M, which is not an achievable concentration for natural 
grazing animals. Foote et al. (2011) also found ergotamine and ergovaline were potent 
vasoconstrictors with relatively lower EC50 (indicator of potency) and higher Emax 
(indicator of efficacy) than other ergot alkaloids in both ruminal arteries and veins, which 
was in agreement with previous saphenous vein studies.  
It may not be appropriate to compare ergot alkaloid’s potency and maximum 
contractile force in an absolute magnitude between this (Foote et al., 2011) and previous 
saphenous vein studies (Klotz et al., 2006; Klotz et al., 2007; Klotz et al., 2008, 2010), since 
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there are differences in several vital setups between the two bioassays (e.g., Instead of 
norepinephrine, 0.12 M KCl was used as a reference compound in ruminal artery and vein 
model. (Klotz et al., 2011)). Nevertheless, taken together, these findings demonstrated 
that both ergotamine and ergovaline are potent vasoconstrictors, while lysergic acid is 
unable to cause vasoconstrictions of bovine tissues under normal physiological conditions. 
 Based on available data (Hill et al., 2001; Ayers et al., 2009), the small intestine 
may be the major absorption site of ergopeptine alkaloids (Strickland et al., 2011). What’s 
more, the mesenteric vein is one of the two outlets of transporting ergot alkaloids after 
they cross the gastrointestinal epithelia, which leads to portal vein and liver (Eckert et al., 
1978). Thus, a bioassay was derived from the previous right ruminal artery and vein model 
(Klotz et al., 2011) to profile the vasoactivity of ergot alkaloids in the bovine mesenteric 
artery and vein (Egert et al., 2014). Similarly, ergocryptine, ergotamine, ergocristine, 
ergocornine, ergonovine, and ergovaline-containing tall fescue seed extract, and 
serotonin were all observed to induce a contractile response on mesenteric artery and 
vein, with the exception of lysergic acid. They also reported that steers with previous 
dietary exposure to endophyte-infested tall fescue seed had decreased or lacked a 
constrictive response to many ergot alkaloids in the small intestine vasculature (Egert et 
al., 2014), which were consistent with the findings in lateral saphenous vein (Klotz et al., 
2012; Klotz et al., 2013). 
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Mechanisms 
Given the studies above, ergot alkaloids associated with endophyte infested tall 
fescue are able to induce vascular contraction in multiple tissues of different animal 
models.  Therefore, they have been attributed as the major causative agents of fescue 
toxicosis. The core ergoline ring system of ergot alkaloids shares some structural 
similarities with several biogenic amines (i.e., (nor)epinephrine, serotonin, and dopamine) 
(Weber, 1980), which may confer to ergot alkaloids the ability to interact with 
corresponding biogenic amine receptors (Berde, 1980). Several pharmacological 
researchers have provided evidence of α-adrenergic receptors that are associated with 
ergot alkaloids and blood vessel interactions (Byrne-Quinn, 1964; Fedotin and Hartman, 
1970; Greene et al., 1977). Although the exact mechanisms behind them are not fully 
defined, several in vitro vascular studies in livestock have reported that ergot alkaloids 
induced vasoactivity is mediated via several biogenic amine receptors (Table 1.2).  
One of the first reports of ergot alkaloids interacting with serotonergic receptors 
was demonstrated by Dyer (1993). He reported that ergovaline induced contractions of 
bovine uterine and umbilical arteries were blocked by ketanserin and phenoxybenzamine 
(both 5HT2A antagonist) but not by prazosin or phentolamine (both α1-adrenergic 
antagonist), which indicated 5HT2A receptors but not α1-adrenergic receptors were 
involved in the vasoconstriction. In contrast, Schoning et al. (2001) found that the 
ergovaline induced rat thoracic aorta contractile response was via α1-adrenergic 
receptors. They also reported that ergovaline and ergotamine are equally effective as a 
partial agonist in rat tail artery, and their vasoconstrictive responses were antagonized by 
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ketanserin (5HT2A antagonist), which was in agreement with Dyer’s findings. What’s more, 
these two studies both indicated that the binding of ergovaline and 5HT2A serotonergic 
receptor was irreversible, and the dissociation from the receptor was slow (Dyer, 1993; 
Schoning et al., 2001). In the latter study, ergovaline also induced contractile responses 
in guinea pig iliac artery via the 5HT1B/1D serotonergic receptor, and interestingly, it acted 
as an agonist and (or) antagonist at the 5HT1B/1D receptor. However, Oliver et al. (1993) 
demonstrated that lysergamide (ergine) was a partial agonist or antagonist at α1-
adrenergic and α2-adrenergic receptors, respectively, in a bovine lateral saphenous vein 
model. Likewise, lysergamide could induce contraction of saphenous vein via 5HT2A 
receptors but not 5HT1 receptors (Oliver et al., 1993). Using the same bovine lateral 
saphenous vein model, Klotz et al. (2012) found DOI (5HT2A receptor agonist) induced 
vessel contractile intensities were 35% lower (P < 0.05) in high endophyte-infested tall 
fescue than in low endophyte-infested tall fescue, whereas 5CT (5HT7 receptor agonist) 
produced greater (37%, P < 0.05) contractile intensities in high endophyte-infested tall 
fescue. Therefore, they indicated that chronic exposure to ergot alkaloids through grazing 
endophyte-infested tall fescue altered the vasoconstriction via serotonergic receptors, 
but in different manners. In a subsequent study (Klotz et al., 2013) they reported 
ketanserin (5HT2A receptor antagonist) reduced the contractile response to ergovaline, 
ergotamine, and ergocornine, but SB-269970 (5HT7 receptor antagonist) was ineffective 
at altering the contractile response.  
In general (Table 2), there is evidence that ergot alkaloids interact with adrenergic 
and serotonergic receptors as partial agonists or antagonists. The interaction between 
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specific receptor subtypes and ergot alkaloids varies among tissue types, as well as animal 
models. Future studies are necessary to better understand the mechanism of ergot 
alkaloid induced vasoconstriction at the receptor level, which is important to researchers 
in terms of discovering therapeutic solutions for fescue toxicosis. 
Isoflavones  
Introduction 
Phytoestrogens are broadly defined as a group of naturally occurring compounds 
in plants that can exert estrogenic activities (Setchell, 1998). Usually these plant-derived 
nonsteroidal molecules execute more “important” functions in animals than in plants, 
where they mainly function as antioxidants (Anderson and Garner, 1997). The most 
conspicuous character of the phytoestrogens is a diphenolic ring with structural 
similarities of mammalian estrogens (Setchell and Adlercreutz, 1988). It is not surprising 
that phytoestrogens bind to estrogen receptors and act as estrogen agonist or antagonist 
(Shemesh et al., 1972; Verdeal et al., 1980; Barnes and Peterson, 1995; Makela et al., 
1995a; Makela et al., 1995b). This interaction with estrogen receptors offers the 
possibility of phytoestrogens being potential alternatives therapies for several hormone 
dependent conditions, such as cancer, menopausal symptoms, cardiovascular disease and 
osteoporosis (Vitale et al., 2013). The abundant natural sources of phytoestrogens has 
been discovered with the development of screening and identification technologies. 
Although phytoestrogens are restrictedly distributed in the plant kingdom, more than 300 
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plants have been identified so far to induce estrogenic responses in animals (Bradbury 
and White, 1954; Farnsworth et al., 1975; Whitten and Patisaul, 2001).   
There are three major classes of phytoestrogens, isoflavones, coumestans, and 
lignans (Kurzer and Xu, 1997). These have always been the interest of studies from a 
nutritional and health-promoting perspective. Isoflavones are the most commonly 
studied form of phytoestrogens, and are almost exclusively found in the legume 
(Leguminosae/Fabaceae) family (Franke et al., 1994; Reinli and Block, 1996). Soybeans 
and soy products are the major source of dietary isoflavones, and contain genistein, 
daidzein, and glycitein (Murphy, 1982; Coward et al., 1993; Wang and Murphy, 1994). 
Many clinical studies in humans, animals, and cell culture systems have addressed these 
two compounds in terms of investigating the potential health benefits of soy and soy 
products. Other than the soybean, chick peas, red clover, toothed medic, and bluegrass 
are all isoflavone containing sources (Price and Fenwick, 1985). Compared with soybeans, 
red clover contains more varieties of isoflavones, such as genistein, daidzein, biochanin A 
and formononetin (Beck et al., 2005). Structurally, biochanin A and formononetin are the 
4’-methyl ethers of genistein and daidzein, respectively (Figure 4) (Kurzer and Xu, 1997).  
Isoflavones and Impacts on Human and Animal Health 
Long term hormone therapies on postmenopausal women have been reported to 
induce some unexpected side-effects, such as increased risks of breast cancer 
(Investigators, 2002; Beral et al., 2003; Anderson et al., 2004). Thus, finding an alternative 
compound to substitute conventional steroid hormone would be desirable. 
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Phytoestrogens, especially isoflavones, with weak estrogenic action, may be a potential 
candidate. However, substantial evidence has been provided by a variety of clinical 
human trials, animal and cell/tissue culture studies to indicate that isoflavones have 
different beneficial effects on humans in many different ways, such as cardiovascular 
system, osteoporosis, breast and prostate cancer (Anderson and Garner, 1997; Kurzer and 
Xu, 1997; Dixon, 2004; Beck et al., 2005).  
It is not the intent to review the physiological effects of isoflavones on these 
different systems, neither to discuss the mechanisms associated with them. In this section, 
the topic will be mainly focusing on the effects of isoflavones on vasculature and the 
possible cellular or molecular mechanisms behind them.  
Physiological Effects of Isoflavones on Vasculature 
Substantial evidence has been reported on the vasodilative effects of isoflavones 
and their metabolites in different vessel types in humans (Walker et al., 2001; Chin-
Dusting et al., 2004) and rats (Gimenez et al., 1997; Chin-Dusting et al., 2001; Jackman et 
al., 2007; Wu et al., 2010). Some of the first information about isoflavone metabolite 
activities in blood vessels was reported by (Gimenez et al., 1997). They indicated that 
equol induced a modest vasorelaxation with was 10-fold more potent than furosemide 
on precontracted isolated rat aortic rings. As many metabolic studies have found, daidzein 
is metabolized by intestinal bacteria to equol, which has a higher estrogenic potency than 
pure isoflavones (Dixon, 2004; Beck et al., 2005). Equol was also detected in plasma and 
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urine of sheep after intraruminal infusion of formononetin (Braden et al., 1967), as well 
as in sheep grazing clover (Shutt and Braden, 1968).  
Chin-Dusting et al. (2001), using rat isolated aortic rings, reported 17β-oestradiol, 
equol, and four other isoflavone metabolites, dihydrodaidzein, cis-tetrahydrodaidzein, 
trans-tetrahydrodaidzein, and dehydroequol all significantly antagonized contractile 
responses to noradrenaline. What’s more, dose-dependent vasodilatory responses were 
observed in noradrenaline precontracted rat aorta by 17β-oestradiol and five other 
isoflavone metabolites (Chin-Dusting et al., 2001).  
Equol also showed vasorelaxant activity in rat carotid arteries in vitro and rat 
basilar arteries in vivo as a potent compound similar with daidzein  (Jackman et al., 2007). 
This finding was consistent with the vasorelaxant effect of daidzein found in rabbit basilar 
(Torregrosa et al., 2003) and rat mesenteric arteries (Nevala et al., 1998). Other 
isoflavones, formononetin and biochanin A were also reported to relax contracted rat 
aortic rings induced by phenylephrine in a dose-dependent manner (Wu et al., 2010). 
An in vivo study by Chin-Dusting et al. (2004) was the first report of a direct 
dilatory effect of an isoflavone metabolite in humans. They demonstrated that 
dehydroequol caused a significant vascular dilation in the forearm resistance arteries. 
Likewise, brachial artery administration of the isoflavone genistein was reported to 
increase the blood flow of forearm resistance artery, which was interpreted as an 
outcome of vasodilation (Walker et al., 2001). However, the exact mechanisms of 
isoflavone and their metabolites as vasodilators have not been fully elucidated.  
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Substantial human, animal, and cell/tissue culture studies have indicated that 
isoflavones and their metabolites induced vasodilation was mediated by endothelium. 
The endothelium of the vascular system plays important roles on regulating blood flow, 
vascular tone, vascular smooth muscle growth, inflammation, coagulation and fibrinolysis 
(Hall et al., 2005). The release of nitric oxide (NO) mainly triggers the endothelium-
dependent vasodilation, which relaxes the smooth muscle and dilates the vessel. In 
endothelium, NO is produced by endothelial NO synthase (eNOS) (Hall et al., 2005). In 
vitro evidence was provided by several animal trials, which found genistein, daidzein and 
isoflavone metabolites induced vasodilative response was endothelium dependent on rat 
aortic rings (Chin-Dusting et al., 2001), pulmonary arteries (Karamsetty et al., 2001), and 
abdominal aorta (Jiang et al., 2003). In vivo studies reported that brachial artery 
administration of genistein caused vasodilation which was antagonized by eNOS inhibitor 
L-NMMA (Walker et al., 2001). What’s more, both elevated vasodilation and eNOS activity 
were reported in ovariectomised rats consuming dietary isoflavones (Yamaguchi et al., 
2001; Catania et al., 2002). Genomic and non-genomic endoplasmic reticulum-mediated 
activation of eNOS were believed to be responsible for the stimulation of NO production 
by isoflavones (Hall et al., 2005).  
In contrast, genistein and daidzein were reported to cause vasodilative responses 
even when endothelium was denuded in rat aortic arteries (Li et al., 2004), and rat 
mesenteric arteries (Nevala et al., 1998). In addition, Jackman et al. (2007) demonstrated 
that the vasorelaxation of carotid arteries in vitro and basilar artery in vivo to equol was 
independent of endothelium and eNOS activity. At present, there is no exact answer as 
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to whether the vasodilative response to isoflavone and its metabolites is wholly 
endothelium dependent or independent, and the mechanism of isolated isoflavones 
varies among different tissue types of different animal models.  
Interestingly, an in vitro study indicated that genistein-induced vascular relaxation 
of rabbit femoral arteries was partially endothelium-dependent, and a calcium 
antagonistic mechanism was involved after the removal of endothelium (Ji et al., 2002). 
Similarly, Wu et al. (2010) suggested that formononetin caused vasorelaxation in rat 
aortic arteries via both endothelium dependent and independent pathways. They 
reported that the activation of large conductance Ca2+-dependent K+ (BKCa) channels and 
ATP-sensitive K+ channel (KATP) was involved in endothelium independent mechanism. 
Again, more evidences are necessary to better understand the molecular mechanisms of 
isoflavones as a vasodilator.  
Conclusion 
Interaction of Ergot Alkaloids and Isoflavones 
Implantation of steroid hormones have been shown to increase body weight gain of 
calves grazing endophyte-infested tall fescue (Davenport et al., 1993; Bransby et al., 1994; 
Coffey et al., 2001; Aiken et al., 2006). What’s more, growth performance studies have 
reported that addition of clover to infected tall fescue increased steer gain significantly 
(Thompson et al., 1993). The dilution of toxic tall fescue by clover was thought the reason 
for the positive impacts on performance. As mentioned in the last chapter, red clover 
contains a variety of isoflavones, such as genistein, daidzein, biochanin A and 
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formononetin (Beck et al., 2005). It is possible that the isoflavone and ergot alkaloid 
interaction was part of the reason to cause impact in performance mentioned above. 
However, more information about the interaction of ergot alkaloids and isoflavones are 
necessary, especially in terms of its potentially positive effects on fescue toxicosis. 
Objectives 
Substantial evidence has shown that ergot alkaloids and isoflavones are able to elicit 
opposing physiological activities on the vasculature. Ergot alkaloids share some 
structurally similarities with biogenic amines (i.e. dopamine, epinephrine, norepinephrine, 
serotonin) and thus can induce vasoconstriction by binding biogenic amine receptors. On 
the other hand, isoflavones have estrogenic activities and might be able to cause 
endothelium dependent or independent vasorelaxation. Although the exact mechanisms 
of their vascular bioactivities have not been fully defined, current knowledge indicates 
that these vascular reactions are triggered by different mechanisms. Nevala et al. (1998) 
reported that isoflavones relax noradrenaline pre-contracted rat mesenteric arteries. 
Likewise, Egert et al. (2014) demonstrated that ergot alkaloids were vasoactive in bovine 
mesenteric vasculature, as well as dietary exposure to ergot alkaloids decreased the 
contractility of mesenteric vasculature. Thus, it is hypothesized that isoflavones may 
attenuate ergot alkaloid induced vasoconstriction and further alleviate the diminished 
contractility of mesenteric vasculature after pre-exposure to ergot alkaloids. The 
objective of this study is to investigate the interaction of isoflavones and ergot alkaloids 
on vasoactivity of bovine mesenteric vasculature and to determine if pre-incubation with 
formononetin, biochanin A, or ergovaline-containing tall fescue seed extract and their 
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combinations affect the ergotamine-induced contractility of bovine mesentery 
vasculature. 
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 Table 1.1 Substituents of ergopeptide (Hafner et al., 2008). 
Toxin Toxin group Substituent R1 Substituent R2 
Ergocomine Ergopeptide CH(CH3)2 CH(CH3)2 
Ergocristine Ergopeptide CH2C6H5 CH(CH3)2 
Ergotamine Ergopeptide CH2C6H5 CH3 
Ergosine Ergopeptide CH(CH3)C2H5 CH3 
α-Ergocryptine Ergopeptide CH(CH3)2 CH3CHCH2CH3 
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Table 1.2 Ergot alkaloids and their biogenic amine receptors. 
 
 
 
 
Ergot Alkaloid Animal Vessel type Adrenergic receptor class Serotonergic receptor class Citation 
Ergovaline 
Cow 
Uterine and 
umbilical 
artery 
Not by α1-adrenergic receptor 5HT2A Dyer (1993) 
Rat 
Tail artery ND 5HT2A 
Schoning et al. 
(2001) 
Thoracic artery α1-adrenergic receptor ND 
Guinea 
pig 
Iliac artery ND 5HT1B/1D 
Ergotamine Rat Tail artery ND 5HT2A 
Ergine 
(Lysergamide) 
Cattle 
Lateral 
saphenous 
vein 
α1-adrenergic receptor 5HT2A 
Oliver et al. (1993) 
α2-adrenergic receptor Not 5HT1 
Endophyte-
infested tall 
fescue 
Cattle 
Lateral 
saphenous 
vein 
α2-adrenergic receptor ND Oliver et al. (1998) 
ND 
5HT2A 
Klotz et al. (2012) 
5HT7 
5HT2A Klotz et al. (2013) 
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Figure 1.1  Ergoline ring system.(Garner et al., 1993) 
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Figure 1.2 Chemical structures of the common clavine alkaloids, lysergic acid derivatives, and ergopeptine alkaloids.  
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Figure 1.3 General structure of ergopeptine alkaloids. (Hafner et al., 2008) 
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Figure 1.4 Chemical structures of the isoflavones found in legumes. (Kurzer and Xu, 1997) 
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Chapter 2. Materials and Methods 
No live animals were involved this study, so approval from the University of 
Kentucky Animal Care and Use Committee was not required. 
Animals and Tissue Collection  
Five Angus heifers (BW = 639 ± 39 kg) were slaughtered and tissues were collected 
at the University of Kentucky abattoir. After the gastrointestinal tract was removed from 
the carcass, the cecum, ileocecal fold, and the ileal flange were identified as landmarks. 
Within the mesentery supporting the ileal flange, multiple branches of the mesenteric 
artery and vein bundles were dissected out and submerged in oxygenated Krebs-
Henseleit buffer (95% O2/5% CO2; pH= 7.4; 11.1 mM D-glucose; 1.2 mM MgSO4; 1.2 mM 
KH2PO4; 4.7 mM KCl; 118.1 mM NaCl; 3.4 mM CaCl2; 24.9 mM NaHCO3; Sigma Chemical 
Co., St. Louis, MO) for transport to the laboratory. Samples were placed on ice until 
cleaned. At the time of cleaning, surrounding fat and connective tissues were carefully 
dissected away, and mesentery artery and vein were separated under a magnifying lamp 
(2.5 to 5.0X magnification). Cleaned vessels were sliced into 2-mm segments and 
examined under a dissecting scope (Semi 2000-C, Carl Zeiss Inc., Oberkochen, Germany) 
at 12.5X magnification to ensure the usability of the vessels. Cross-sections with 
abnormalities (branches, valves, or structural damage) were replaced with structurally 
integral ones.  
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Pre-myograph Incubations  
A tall fescue seed extract was prepared as described by Foote et al. (2012) to 
contain a 1 × 10-6 M working concentration of ergovaline. Duplicates of each vessel type 
were incubated in tissue culture flasks with a 50-mL volume of Krebs-Henseleit buffer 
containing: only buffer (Control); 1 × 10-6 M ergovaline-containing tall fescue seed extract 
(EXT); 1 × 10-6 M formononetin (F; ≥ 99.0%; 47752-5MG-F; Sigma Chemical Co., St. Louis, 
MO); or 1 × 10-6 M biochanin A (B; D2016; Sigma Chemical Co., St. Louis, MO); and 
combinations of 1 × 10-6 M EXT and 1 × 10-6 M F (EXT + F); 1 × 10-6 M EXT and 1 × 10-6 M 
B (EXT + B); 1 × 10-6 M F and 1 × 10-6 M B (F + B); or 1 × 10-6 M EXT and 1 × 10-6 M F and 1 
× 10-6 M B (EXT + F + B). All buffer solutions were pre-warmed for 30 min in a CO2 
incubator (95% O2/5% CO2; 37 ℃; Nu-8500, NUAIRE, Inc. Plymouth, MN) prior to blood 
vessel addition. Duplicate blood vessel segments were randomly placed into each 
treatment flask and incubated in the same conditions for 2 h. Immediately after the 2-h 
incubation, dimensional measurements of cross-sections were recorded only for 
mesentery artery using Axiovision (version 20, Carl Zeiss, Inc.). 
Experimental Myograph Protocol 
Following the incubations, an ergotamine concentration response experiment was 
conducted using the procedures described by Egert et al. (2014) and Klotz (2014). 
Ergotamine (ergotamine D-tartrate; 97%; 45510; Aldrich, Milwaukee, WI) standards were 
prepared by diluting stock solutions (0.0201 M) with dimethyl sulfoxide to working 
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concentrations that resulted in a concentration range of 5 × 10-9 to 1 × 10-4 M in the 
myograph chamber (contained 5 mL of Krebs-Henseleit buffer).  
Blood vessel cross-sections were gently mounted on the myograph (Multichamber 
myograph; DMT 610M, Danish Myo Technology, Atlanta, GA) by inserting the supports 
through the lumen in individual myograph chambers containing 5 mL modified Krebs-
Henseleit buffer and continuously gassing (95% O2/5% CO2; pH = 7.4; 37℃). The 
incubation buffer was modified from transport Krebs-Henseleit buffer by adding 
desipramine (3 × 10-5 M; D3900; Sigma Chemical Co.) to inhibit the reuptake mechanisms 
of biogenic amines and propranolol (1 × 10-6 M; P0844; Sigma Chemical Co.) to block the 
non-specific binding to β-adrenergic receptors. A 90-min equilibration period with buffer 
replacement occurring every 15 min was completed based on the conditions above to 
achieve a stable resting tension of approximately 1 g. After the completion of 
equilibration, 500 μL of a 1.32 M KCl (Sigma Chemical Co.) solution, resulting in a 120 mM 
KCl in a myograph chamber, was added and incubated for 15 min to evaluate tissue 
viability and to be used to normalize treatment data. Incubation buffer was replaced 
every 15 min until vessel tension returned to the 1 g baseline. Once the vessel returned 
to baseline, addition of ergotamine standards were initiated in order of increasing 
concentration. Ergotamine additions were added in 15-min intervals consisting of a 9-min 
incubation period, two 2.5-min buffer washes, and a third, final buffer replacement that 
was followed by 1-min recovery before the next ergotamine addition. This 15 min cycle 
was repeated for the rest of the 9 remaining ergotamine additions. Following the 1-min 
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recovery after the final ergotamine addition, vessels were again exposed to 120 mM KCl 
to confirm the vessel viability at the end of the experiment. 
Data Collection and Statistical Analysis  
The isometric contractions of the different pre-incubated mesenteric vessels to 
KCl and ergotamine additions were digitized and recorded as grams of tension using a 
PowerLab/8sp and Chart software (version 7.3, ADInstruments, Colorado Springs, Co.). 
Baseline tension was measured immediately before the addition of 1.32 M KCl. For all 
contractile response data, the maximum observed tension (g) in the 9 min-incubation 
period was recorded as the contractile response. Contractile response data were 
corrected for baseline tension (subtraction of the baseline measurement) and normalized 
as a percentage of the reference compound KCl induced maximum contractile response 
(grams of tension). The differences of tissue response due to the variations of vessel size 
and individual animal were taken into account by this data normalization. The contractile 
response to ergotamine was determined and presented as percentage means ± SEM. A 
measurement of potency, or the half maximal effective concentration (EC50) was 
calculated by GraphPad Prism software 5 (GraphPad Software Inc., La Jolla, CA) using a 
nonlinear regression with fixed slope. The sigmoidal concentration response curves of 
pre-treated mesentery artery and vein to ergotamine was plotted by using a 3-parameter 
equation: 
𝑦 = bottom +
(top−bottom)
[1+10(𝑙𝑜𝑔𝐸𝐶50−𝑥)]
 , 
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where top and bottom are the plateaus of contractile response as percentage of 120 mM 
KCl maximum response. EC50 is the molar concentration of ergotamine inducing 50% of 
the KCl maximum response. 
All data were analyzed using the MIXED model of SAS (SAS 9.4, SAS Inst. Inc., Cary, 
NC). Contractile response data of mesentery artery and vein were analyzed separately as 
two groups: treatments with and without EXT. Data for contractile response (within each 
ergotamine concentration), KCl maximal response, inside and outside diameters for 
mesenteric artery (data could not be obtained for mesenteric vein samples) were 
analyzed as a completely randomized design with a factorial treatment arrangement. The 
fixed effects included the effects of F, B, and the interaction of F × B in the presence or 
absence of EXT. Due to the shape of the response curve, EC50 data were analyzed only in 
treatments without EXT from mesentery artery using a completely randomized design 
with treatment as fixed variable. For all data, an ANOVA was conducted and pair-wise 
comparisons of least square means (± SEM) were performed if the probability of a greater 
F-statistic was significant for the tested effect and interaction. Mean separation was 
performed with the LSD feature of SAS. Differences are denoted as significant at P < 0.05, 
unless specifically reported otherwise.  
Chapter 3. Results 
The F and B incubation pre-treatment did not impact (P > 0.05) the maximum 
contractile response of mesenteric artery or mesenteric vein to 120 mM KCl either 
without EXT (Table 3.1) or with EXT (Table 3.2). The pre-treatments with EXT did not 
 38 
 
compromise the vessel viability, which was indicated by the ending response to KCl for 
either the artery or vein (Figure 3.1). In mesenteric artery, the inside and outside diameter 
after the 2 h incubation were not affected (P > 0.05) by F or B in both treatments groups 
with or without EXT (Table 3.1, Table 3.2). However, these was a tendency (P < 0.1) for F 
treated vessels to have a larger inside diameter for those pretreated with EXT, and a 
smaller outside diameter for those pretreated without EXT (Table 3.2). 
In the mesenteric artery, ergotamine induced similar contractile responses in all 
treatments (Figure 3.2a) with -logEC50 values (5.99 ± 0.14 M, 5.80 ± 0.14 M, 5.88 ± 0.14 
M, 5.74 ± 0.14 M, respectively) that did not differ with each other (P = 0.6338). Within 
each ergotamine concentration, tendencies for F × B interactions in mesenteric artery 
were observed at ergotamine 5 × 10-9 M, 1 × 10-8 M, 5 × 10-8 M (P = 0.0932, P = 0.0703, P 
= 0.0840, respectively; Table 3.3) for treatments without EXT. Contractile responses of F 
+ B treated mesentery artery were greater than B at ergotamine concentrations 1 × 10-8 
M and 5 × 10-8 M (P < 0.05). In mesenteric vein, ergotamine induced contractile responses 
reached the maximum response at 1 × 10-6 M for Control, B, F, F + B treatments (Figure 
3.2b), and then declined to negative values with increases in ergotamine concentration.  
For the blood vessels incubated with EXT the contractile responses decreased as 
the concentration of ergotamine increased in both mesenteric artery and mesenteric vein 
(Figure 3.2c, 3.2d). In mesenteric artery, a main effect of B was observed at ergotamine 
concentrations of 1 × 10-7 M and 5 × 10-7 M (Table 3.4), with treatments that contained B 
having higher contractile responses (P < 0.05). Also, treatments containing B tended (P < 
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0.1) to have greater responses than treatments without B at ergotamine concentrations 
of 1 × 10-6 M, 5 × 10-6 M, and 5 × 10-5 M (Table 3.4).  
In the mesenteric vein, the contractile response of all treatments with EXT to 
ergotamine decreased and remained below zero from the second ergotamine addition (1 
× 10-8 M) to the last addition at 1 × 10-4 M. Tendencies for main effects of B (P = 0.06) and 
a F × B interaction (P = 0.09) were observed at ergotamine concentrations of 5 × 10-9 M, 
where EXT treatment had a lower contractile response than EXT + B (P < 0.05; Table 3.4). 
Treatments containing F had greater contractile responses to ergotamine at 1 × 10-5 M, 5 
× 10-5 M, and 1 × 10-4 M in mesenteric vein (main effect of F; P < 0.05; Table 3.4). Within 
ergotamine concentrations, at 5 × 10-5 M the contractile response of EXT was the lowest 
(P < 0.05).  
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Table 3.1 Inside diameter, outside diameter and SEM of mesenteric artery, and the mean KCL maximum response of mesenteric artery and vein 
to pre-treatment without tall fescue extract: only Krebs-Henseleit buffer (Control); 1 × 10-6 M formononetin (F); or 1 × 10-6 M biochanin A (B); 
and combination of 1 × 10-6 M F and 1 × 10-6 M B (F + B) 
 
1 F, main effect of formononetin; B, main effect of biochanin A; F x B, interaction of formononetin and biochanin A. 
 
 
 
 
 
Item Control F B F + B SEM 
P-value1 
F B F x B 
Mesenteric artery 
KCL maximum response, g 4.36 4.42 4.22 3.66 0.46 0.5837 0.3319 0.4951 
Inside diameter, mm 0.81 0.79 0.86 0.77 0.06 0.3774 0.7714 0.6142 
Outside diameter, mm 1.72 1.64 1.75 1.57 0.07 0.0901 0.7440 0.4721 
Mesenteric vein 
KCL maximum response, g 1.70 1.81 1.89 2.22 0.21 0.3115 0.1784 0.6160 
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Table 3.2 Inside diameter, outside diameter and SEM of mesenteric artery, and the mean KCL maximum response of mesenteric artery and vein 
to pre-treatment with tall fescue seed extract: 1 × 10-6 M ergovaline-containing tall fescue seed extract (EXT); combinations of 1 × 10-6 M EXT 
and 1 × 10-6 M F (EXT + F); 1 × 10-6 M EXT and 1 × 10-6 M B (EXT + B); or 1 × 10-6 M EXT and 1 × 10-6 M F and 1 × 10-6 M B (EXT + F + B). 
 
1 F, main effect of formononetin; B, main effect of biochanin A; F x B, interaction of formononetin and biochanin A. 
 
 
 
 
 
Item EXT EXT + F EXT + B EXT + F + B SEM 
P-value1 
F B F x B 
Mesenteric artery 
KCL maximum response, g 3.43 2.68 3.08 2.84 0.37 0.1887 0.8022 0.5010 
Inside diameter, mm 0.72 0.78 0.60 0.72 0.05 0.0742 0.0649 0.5034 
Outside diameter, mm 1.64 1.57 1.51 1.59 0.07 0.9189 0.4256 0.2855 
Mesenteric vein 
KCL maximum response, g 1.90 2.20 2.09 2.49 0.21 0.1110 0.2646 0.8146 
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Table 3.3  The analysis of variance and P-values of main effect of formononetin (F), biochanin A (B), and the interaction of formononetin and 
biochanin A (F x B) for pre-treatments without tall fescue extract: only Krebs-Henseleit buffer; 1 × 10-6 M formononetin; or 1 × 10-6 M biochanin 
A; and combination of 1 × 10-6 M formononetin and 1 × 10-6 M biochanin A on every ergotamine concentration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 F, main effect of formononetin; B, main effect of biochanin A; F x B, interaction of formononetin and biochanin A. 
 
Ergotamine 
Concentration, M 
P-value1 
F B F x B 
Mesenteric artery 
5x10-9 
 
0.2281 0.9117 0.0932 
1x10-8 0.1446 0.2723 0.0703 
5x10-8 0.1963 0.5085 0.0840 
1x10-7 0.2943 0.8303 0.3059 
5x10-7 0.8788 0.7897 0.4319 
1x10-6 0.6784 0.7843 0.6378 
5x10-6 0.2674 0.9888 0.7172 
1x10-5 0.3790 0.9720 0.9700 
5x10-5 0.4322 0.8098 0.7747 
1x10-4 0.6140 0.5352 0.5949 
Mesenteric vein 
5x10-9 
 
0.9175 0.2667 0.8545 
1x10-8 0.9963 0.9648 0.5015 
5x10-8 0.6737 0.6700 0.2827 
1x10-7 0.7952 0.6422 0.4082 
5x10-7 0.9871 0.4340 0.7427 
1x10-6 0.9304 0.2983 0.7009 
5x10-6 0.7795 0.4265 0.6996 
1x10-5 0.5048 0.7964 0.6229 
5x10-5 0.2860 0.9309 0.6051 
1x10-4 0.2286 0.8638 0.8886 
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Table 3.4 The analysis of variance and P-values of main effect of formononetin (F), biochanin A (B), and the interaction of formononetin and 
biochanin A (F x B) for pre-treatments with tall fescue seed extract: 1 × 10-6 M ergovaline-containing tall fescue seed extract; combinations of 1 × 
10-6 M ergovaline-containing tall fescue seed extract and 1 × 10-6 M formononetin; 1 × 10-6 M ergovaline-containing tall fescue seed extract and 1 
× 10-6 M biochanin A; or 1 × 10-6 M ergovaline-containing tall fescue seed extract and 1 × 10-6 M formononetin and 1 × 10-6 M biochanin A on 
every ergotamine concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 F, main effect of formononetin; B, main effect of biochanin A; F x B, interaction of formononetin and biochanin A. 
Ergotamine 
Concentration, M 
P-value1 
F B F x B 
Mesenteric artery 
5x10-9 
 
0.9418 0.7127 0.6984 
1x10-8 0.4289 0.3081 0.9555 
5x10-8 0.2200 0.1114 0.7707 
1x10-7 0.2009 0.0438 0.7342 
5x10-7 0.2482 0.0302 0.5680 
1x10-6 0.2109 0.0572 0.5798 
5x10-6 0.2131 0.0863 0.5240 
1x10-5 0.3070 0.1269 0.6992 
5x10-5 0.2432 0.0975 0.8691 
1x10-4 0.1788 0.1170 0.7737 
Mesenteric vein 
5x10-9 
 
0.7453 0.0694 0.0976 
1x10-8 0.9145 0.7666 0.4060 
5x10-8 0.4529 0.9824 0.5007 
1x10-7 0.1753 0.8547 0.3217 
5x10-7 0.1483 0.4810 0.1878 
1x10-6 0.1872 0.5756 0.3217 
5x10-6 0.1566 0.4390 0.2674 
1x10-5 0.0339 0.3013 0.1160 
5x10-5 0.0212 0.1711 0.0794 
1x10-4 0.0059 0.2382 0.1359 
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Figure 3.1 Example of a typical response of mesenteric artery (a) and vein (b) cross sections, after pre-treated with 1 × 10-6 M EXT and 1 × 10-6 M 
F and 1 × 10-6 M B (EXT + F + B),  to increasing concentrations of ergotamine (5 × 10-9 to 1 × 10-4 M). The rectangles highlighted region are the 
initial and end KCl (0.12 M) additions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Te
n
si
o
n
, g
 
Te
n
si
o
n
, g
 
(a) 
(b) 
   
4
5
 
Figure 3.2 Mean contractile response, as % KCl maximum of mesenteric artery (a, c) and vein (b, d) to increasing concentrations of ergotamine for 
two groups of pre-treatments, without tall fescue seed extract: only Krebs-Henseleit buffer (Control); 1 × 10-6 M formononetin (F); or 1 × 10-6 M 
biochanin A (B); and combination of 1 × 10-6 M F and 1 × 10-6 M B (F + B) (a, b); with tall fescue seed extract: 1 × 10-6 M ergovaline-containing tall 
fescue seed extract (EXT); combinations of 1 × 10-6 M EXT and 1 × 10-6 M F (EXT + F); 1 × 10-6 M EXT and 1 × 10-6 M B (EXT + B); or 1 × 10-6 M EXT 
and 1 × 10-6 M F and 1 × 10-6 M B (EXT + F + B) (c, d). The regression lines were plotted of each treatment using a nonlinear regression with fixed 
slope and the sigmoidal concentration response curves were calculated by the following equation: y = bottom + [(top-bottom)/(1 + 10(𝑙𝑜𝑔𝐸𝐶50−𝑥))], 
where top and bottom are the plateaus of contractile response as percentage of 120 mM KCl maximum response. EC50 is the molar concentration 
of ergotamine inducing 50% of the KCl maximum response. 
 
 
 
 
 
 
 
 
 
 
 
 
(a) (b) 
(c) (d) 
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Chapter 4. Discussion and Conclusion 
To our knowledge, this study was the first to investigate the interaction of 
ergoalkaloids and isoflavones on in vitro mesenteric vasculature. Physiological effects of 
isoflavones and their metabolites on vasculature have been extensively studied on 
different vessel types in humans (Walker et al., 2001; Chin-Dusting et al., 2004), and rat 
models (Gimenez et al., 1997; Chin-Dusting et al., 2001; Jackman et al., 2007; Wu et al., 
2010). However, to date, isoflavones’ vasoactivity have not been studied in bovine 
mesenteric vasculature.  
Several studies have demonstrated that cattle grazing endophyte-infected tall 
fescue had reduced contractile responses to 5HT and as well as ergot alkaloids in the 
lateral saphenous vein (Klotz et al., 2012; Klotz et al., 2013). Recently, a study using 
mesenteric artery and vein from steers that had been intraruminally dosed with 
endophyte-infected tall fescue seed observed a decreased or absent constrictive 
response to ergot alkaloids (Egert et al., 2014). In the current study, an in vitro pre-
myograph incubation of bovine mesenteric vasculature in the medium containing 
endophyte-infected tall fescue seed extract was used to achieve an ergot alkaloid pre-
treatment. The endophyte-infected tall fescue seed extract (Foote et al., 2012) and 
isoflavones (formononetin and biochanin A) were added to the myograph medium at 
equimolar final concentrations of 1 × 10-6 M. It has been reported that formononetin and 
biochanin A both induced vasorelaxation in phenylephrine precontracted rat isolated 
thoracic aorta at 1 × 10-6 M (Wu et al., 2010). However, the 1 × 10-6 M ergovaline in the 
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endophyte-infected tall fescue seed extract may be considered a high dose compared to 
the physiological level encountered by cattle grazing endophyte-infected tall fescue. 
Nevertheless, the viability of mesenteric artery and vein were not compromised by these 
amounts of ergot alkaloids which was supported by the fact that they were both active to 
the ending KCl addition.   
Studies have reported that many isoflavones and their metabolites can reduce the 
vasoconstriction induced by KCl in several different vessel types using rat models (Jiang 
et al., 1991; Jackman et al., 2007). The contractile response to KCl of endothelium 
denuded rat aortic rings was inhibited by pretreatment with genistein or daidzein at both 
30 and 100 μM for 30 min (Seok et al., 2008). However, in the same study, pretreatment 
with genistein or daidzein at 10 μM did not induce the vasorelaxation caused by KCl. The 
similar dose-dependent inhibition of formononetin (10, 30, and 100 μM) on the 
contractile response to KCl was observed in rat mesenteric arteries without endothelium 
(Sun et al., 2011), where formononetin again failed to inhibit KCl-initiated contraction at 
10 μM. However, in endothelium-intact rat aortic rings, Zhao et al. (2012) reported that 
pretreatment with 10, 30, and 50 μM of formononetin all significantly inhibited the 
contractile response to KCl in a noncompetitive manner. In the current study, the prior 
exposure to formononetin (1 μM), biochanin A (1 μM), and their combination did not have 
an impact on maximum contractile response of mesenteric artery and vein to KCl in 
treatments either with or without EXT. Since previous studies have indicated that the 
inhibition effects were dose-dependent (Seok et al., 2008; Sun et al., 2011) and 
noncompetitive (Zhao et al., 2012), it is possible the isoflavone concentration (1 μM) in 
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the current study was not high enough to elicit any inhibitory effects. However, in the 
current study, from a perspective of reference compounds to normalize the contractile 
responses, the unaffected maximum KCl response by formononetin and biochanin A were 
critical.  
There is limited information about isoflavones’ impact on blood vessel 
morphology in regards to vessel inside and outside diameters. In the current study, there 
was no evidence of a formononetin or biochanin A effect on mesenteric artery inside or 
outside diameter regardless of EXT treatment. However, a tendency of smaller inside 
diameter induced by formononetin treatment was observed in mesentery artery pre-
treated without EXT. One possible explanation for this could be the inhibitory effect of 
formononetin on vascular smooth muscle cells. Previously, estrogens (tamoxifen 
(Grainger and Metcalfe, 1996), estradiol (Rosselli et al., 1994)) and phytoestrogens 
(formononetin and biochanin A (Dubey et al., 1999) have been shown to inhibit mitogen-
induced proliferation, migration and extracellular matrix synthesis of smooth muscle cells. 
On the other hand, the inside diameter of bovine lateral saphenous veins collected from 
steers grazing high-endophyte tall fescue pasture were smaller than those from steers 
grazing low-endophyte mixed-grass pasture (Klotz et al., 2012). Likewise, Egert et al. 
(2014) observed a smaller outside diameter of bovine mesenteric artery from endophyte-
infected tall fescue seed dosed steers than control steers. One possible explanation is the 
prolonged vasoconstriction induced by ergot alkaloids result in decreased inside or 
outside diameter. Additionally, the morphological changes of blood vessels, especially the 
expansion of the smooth muscle layer (tunica media), could also lead to a smaller vessel 
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insider diameter. It has been observed that calves given ethanolic extracts of tall fescue 
hay had symptoms of fescue foot and concomitant thickening of vessel walls and smaller 
vessel lumens in blood vessels of the coronary bands and tail tips (Williams et al., 1975). 
Similarly, Garner and Cornell (1978) reported a thickening of the smooth muscle layer of 
peripheral blood vessels after consumption of endophyte-infected tall fescue. Although 
the exact mechanism associated with thickening of smooth muscle layer is unclear, 
evidence suggests hyperplasia over hypertrophy. Strickland et al. (1996) reported that 
ergonovine, ergovaline and α-ergocryptine stimulate the growth and mitosis of quiescent 
bovine vascular smooth muscle cells in vitro. Although, in this study, there was no 
significant impact of formononetin and biochanin A pre-treatment on mesenteric artery 
inside or outside diameters, tendencies of larger inside diameter caused by formononetin 
and smaller inside diameter in biochanin A treated mesenteric artery were observed. This 
controversial observation could not be well explained based on our current knowledge. 
However, besides vasoconstriction and vasodilation, many other factors could influence 
the inside or outside diameter, such as vascular smooth muscle hyperplasia and 
hypertrophy.  
In the current study, the ergotamine induced similar contractile response curves 
in mesenteric artery, and with –logEC50 values that did not differ among treatments 
without EXT. The shape of contractile responses were similar with Egert et al. (2014), who 
reported ergotamine induced contractile responses in mesenteric artery from steers, not 
exposed to ergot alkaloids, with a –logEC50 value of 6.03 ± 0.4 M. Whereas, in mesenteric 
vein, the shape of contractile response curves were in contrast to the observations of 
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Egert et al. (2014), which did not drop to negative values after peak. Further, the 
maximum contractile response of mesenteric vein to ergotamine in the current study was 
also lower (10% vs. 45% of KCl maximum). It has to be mentioned that the blood vessels 
used in the previous study (Egert et al., 2014) did not undergo pre-myograph incubation. 
So, taken together, the 2-hr pre-myograph incubation in the current study seemed to alter 
the contractile response of mesenteric veins in terms of potency and efficacy to 
ergotamine.  
Substantial evidence has shown many ergot alkaloids are vasoconstrictive in 
multiple tissues of different animal models (Strickland et al., 2009b; Strickland et al., 
2011). Among these vasoactive ergot alkaloids, ergotamine and ergovaline were indicated 
as more potent vasoconstrictors with relatively lower EC50 values in bovine saphenous 
vein (Klotz et al., 2007), ruminal vasculature (Foote et al., 2011), and mesenteric 
vasculature (Egert et al., 2014). The current observation of the contractile response 
induced by ergotamine was consistent with these previous findings. Even though not 
completely defined yet, numerous studies have been conducted to investigate the 
mechanism of ergot alkaloid-caused vasoconstriction. The structural similarities of the 
ergoline ring system and several biogenic amines (i.e., (nor)epinephrine, serotonin, and 
dopamine) allows ergot alkaloids to interact with corresponding biogenic amine receptors 
as ligands (Berde, 1980; Weber, 1980). Substantial evidences have shown that ergot 
alkaloids interact with dopamine-2 receptor (Larson et al., 1994; Larson et al., 1995), α1-
adrenergic receptor (Oliver et al., 1993; Schoning et al., 2001), α2-adrenergic receptor 
(Oliver et al., 1998), 5HT2A receptor (Dyer, 1993; Klotz et al., 2012; Klotz et al., 2013). The 
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binding with these G protein-coupled receptors activates the subunit of the 
heterotrimeric G protein and then triggers various secondary messaging systems and 
corresponding cytoplasmic signaling transductions. 
The pre-myograph incubation with EXT altered the contractile capacity in a 
manner similar with previous studies. Using a bovine lateral saphenous vein model, Klotz 
et al. (2012) found DOI (5HT2A receptor agonist) induced vessel contractile intensities 
were 35% lower in high endophyte-infested tall fescue than in low endophyte-infested 
tall fescue, whereas 5CT (5HT7 receptor agonist) produced greater (37%) contractile 
intensities in high endophyte-infested tall fescue. Therefore, they indicated that chronic 
exposure to ergot alkaloids through grazing endophyte-infested tall fescue altered the 
vasoconstriction via serotonergic receptors, but in different manners. In a subsequent 
study (Klotz et al., 2013) they reported a suppression of the contractile response to 
ergovaline and 5HT in steers grazing Kentucky-31 tall fescue infected with wild-type 
endophyte. What’s more, Egert et al. (2014) showed the similar observation of reduced 
contractile response to ergotamine in mesenteric vasculature of steers exposed with 
endophyte-infected tall fescue seed. Taken together, it is possible that the EXT pre-
treatment might have reduced the vasoconstriction to ergotamine via altering the 
potential biogenic amine receptor populations and activities, for example, the 
antagonistic effects of ergot alkaloids to certain 5HT receptors have been shown 
previously (Oliver et al., 1993; Pertz and Eich, 1999; Schoning et al., 2001). Although the 
exact mechanisms are unknown, it is possible these alterations are mediated by the 
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downreulation of gene transcription associated with secondary messaging pathways of G 
protein-coupled receptors by ergot alkaloids (Maurer, 1981). 
What’s more, many in vitro bioassays have proposed, in various vessel types and 
in many different species, the binding of ergovaline and receptor was irreversible, or the 
dissociation from the receptor was very slow (Dyer, 1993; Schoning et al., 2001; Klotz et 
al., 2007; Pesqueira et al., 2014). Likewise, the bioaccumulation effect was reported in 
bovine lateral saphenous veins after repetitive exposure of ergovaline in vitro (Klotz et al., 
2009). These findings may explain the differences of contractile response to initial 
ergotamine addition (5 × 10-9 M) between mesenteric artery incubated with or without 
endophyte-infected tall fescue seed extract. It is possible that during the two hour pre-
incubation with endophyte-infected tall fescue seed extract, the corresponding receptors 
have been irreversibly bound by ergot alkaloids (mainly 1 × 10-6 M ergovaline) present in 
the endophyte-infected tall fescue seed extract. This speculation was further validated by 
the observation that the initial contractile response to ergotamine by EXT (containing 1 × 
10-6 M ergovaline) incubated mesenteric artery was numerically similar to 1 × 10-6 M 
ergotamine induced contractile response of mesenteric artery without EXT incubation. It 
has been demonstrated that ergotamine and ergovaline are both potent vasoconstrictor 
inducing similar contractile responses (Klotz et al., 2007). 
In the present study, formononetin and biochanin A failed to offset the mesenteric 
vasculature contraction induced by ergotamine. As discussed earlier in this section, 
numerous studies have shown the vasodilative effect of isoflavones and their metabolites 
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in different vessel types. Pretreatment with formononetin (30 and 50 μM) antagonized 
contractile responses of rat thoracic aortas to norepinephrine in a noncompetitive 
manner (Zhao et al., 2012). Sun et al. (2011) hypothesized that pre-incubation with 
formononetin (30 and 100 μM) depressed the contraction of rat mesenteric artery to 
phenylephrine and 5-HT, and similarly, depression was not observed when formononetin 
at 10 μM.  Again, the 1 μM formononetin and biochanin A in the present study were 
possibly not in high enough concentrations to elicit vasorelaxations. Other evidence of 
the chronic antihypertensive effect of formononetin has been reported based on male 
spontaneously hypertensive rats (SHR) (Sun et al., 2013). They found that the 
vasoconstriction of mesenteric artery segments induced by phenylephrine or 5-HT was 
reduced in formononetin (50 mg/kg per day) orally administrated SHR. What’s more, the 
expression of α1-adrenoceptors and 5-HT2A/1B receptors in mesenteric artery of 
formononetin treated SHR decreased (Sun et al., 2013).  Even though there might be some 
species differences between bovine and SHR, the two hour pre-myograph incubation with 
formononetin or biochanin A in the present study may be not long enough to trigger 
certain consequences.   
With EXT in the pretreatment media, formononetin and biochanin A increased the 
contractile response of mesenteric artery at several ergotamine concentrations. This has 
provided the first evidence that the isoflavones, formononetin and biochanin A have 
potential to alleviate the inhibitory effect of ergot alkaloids. However, current knowledge 
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from ergot alkaloids and isoflavones are unable to explain this phenomenon, so more 
investigations on their interaction are needed.  
In conclusion, this study indicated that a pre-myograph incubation with 
formononetin, biochanin A at 1 × 10-6 M and their combination did not affect the 
contractile response to ergotamine in mesenteric vasculature. The pre-myograph 
incubation of mesenteric vasculature with endophyte-infected tall fescue seed extract 
(equivalent to 1 × 10-6 M ergovaline) reduced the vasoactivity of ergotamine. At higher 
concentrations, formononetin and biochanin A may alleviate this reduction in vasoactivity 
caused by prior exposure to ergot alkaloids. However, no current data are available to 
fully support this observation, and future investigations are necessary to understand the 
mechanism behind the interaction of ergot alkaloids and isoflavone. 
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